Pembrolizumab is a humanized PD-1 monoclonal antibody used for cancer immunotherapy. It currently has the most approved indications, as well as it is used in more tumors’ treatments than other drugs are. China approved Pembrolizumab’s first indication in China in 2018, and approved for five more until 2020, including melanoma; single-agent or combined chemotherapy for first-line treatment with positive PD-L1 expression and no EGFR or ALK mutations locally advanced or metastatic non-small cell lung cancer; PD-L1 tumor proportion score (TPS) ≥ 1% EGFR gene mutation (negative) and ALK (negative) first-line monotherapy for locally advanced or metastatic non-small cell lung cancer; first-line treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC); second-line treatment for esophageal cancer; and first-line monotherapy for head squamous cell carcinoma (HNSCC).
According to the analyst's market research, after Pembrolizumab entered the Chinese market, its sales revenue has increased several times. The revenue in 2020 reaches approximately CNY 294.75 million, and the CAGR is 284.67% from 2018 to 2020. Thus, the analyst analyzes that the market size of Pembrolizumab will expand in the future due to the increased numbers of approved indications.
In addition, PD-1-type drug is not very common in the Chinese market, so Merck Sharp & Dohme Corp, as the only supplier of Pembrolizumab in China, did not face any threat in the past. However, in December 2018, a PD-1 drug produced by Junshi Biosciences has been successfully approved for marketing. Therefore, the analyst predicts that from 2021 to 2025, the price of Pembrolizumab in China may be lowered, but the market will continue to expand due to Pembrolizumab’s effectiveness and unsaturated demand.
- The impact of COVID-19 on China's pembrolizumab market
- Sales value and volume of China's pembrolizumab 2016-2020
- Competitive landscape of China's pembrolizumab market
- Prices of pembrolizumab in China
- Prices of pembrolizumab in China by regions and manufacturers
- Analysis of factors affecting the development of China's pembrolizumab market
- Prospect of China's pembrolizumab market from 2021 to 2025
1 Relevant Concept of Pembrolizumab
1.1 Indications for Pembrolizumab
1.2 Development of Pembrolizumab in China
1.3 Governmental Approval of Pembrolizumab in China
1.4 The Impact of COVID-19 on Pembrolizumab sales in China
2 Sales of Pembrolizumab in China, 2018-2020
2.1 Sales Value of Pembrolizumab
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Pembrolizumab
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Pembrolizumab by Dosage Form in China, 2018-2020
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Pembrolizumab Manufacturers in China, 2018-2020
3.1 Analysis of Market Share of Major Pembrolizumab Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Merck Sharp & Dohme Corp
3.2.1 Enterprise Profile
3.2.2 Sales of KEYTRUDA (Merck's Pembrolizumab) in China
4 Price of Pembrolizumab in China, 2020-2021
4.1 Merck Sharp & Dohme Corp (KEYTRUDA)
5 Prospect of Chinese Pembrolizumab drug Market, 2021-2025
5.1 Influential Factors of Chinese Pembrolizumab Market Development
5.1.1 The Impact of COVID-19 on Chinese Pembrolizumab Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information About Pembrolizumab Injection Registration in China
Chart Sales Value of Pembrolizumab Injection over the World
Chart Sales Value of Pembrolizumab Injection in China, 2018-2020
Chart Sales Value of Pembrolizumab Injection in China by Regions, 2018-2020
Chart Sales Volume of Pembrolizumab Injection in China, 2018-2020
Chart Sales Volume of Pembrolizumab Injection in China by Regions, 2018-2020
Chart Sales Value and Volume of KEYTRUDA in China, 2018-2020
Chart Referential Prices of KEYTRUDA in China, 2020-2021
Chart Forecast on Sales Value of Pembrolizumab in China, 2021-2025
Chart Forecast on Sales Volume of Pembrolizumab in China, 2021-2025
- Merck Sharp & Dohme Corp
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.